To say that Hologic is making good use of the capital gained from its stellar COVID-19 diagnostics sales might be an understatement. The Waltham, MA-based company has announced no less than five acquisitions this year, positioning itself to become a diversified leader in the diagnostics space.

The company kicked off 2021 with the $64 million acquisition of Somatex Medical Technologies and announced its $230 million deal to acquire Biotheranostics. Somatex helped Hologic expand its presence in breast health with minimally invasive devices in the areas of tumor diagnostics, biopsy, and interventional specialties. Through Biotheranostics, Hologic inherited polymerase chain reaction (PCR) gene expression oncology tests with high-growth potential, including breast cancer.

By March it was evident that the company had no intention of slowing its roll, as it acquired Diagenode for $159 million. Diagenode developed Diagenode provides more than 30 real-time PCR tests that are CE-marked for the detection of bacteria, parasites, and viruses involved in sexually transmitted infections, respiratory diseases, meningitis, and gastroenteritis.

Hologic also ponied up $795 million for Mobidiag Oy and $160 million for Bolder Surgical this year.